Guided by the state-driven import replacement strategy, Pharmeco has been growing its R&D operations since 2014.

Our goal is to grow domestic production of socially critical preparations and thereby make quality and safe medicines available to broad public.

Pharmeco Group’s manufacturing sites deliver a wide range of products for Russian healthcare: proprietary medicines as well as innovative drugs from international companies and those localised in the Russian Federation. All of the Group’s pharmaceutical factories comply with GMP standards.

The Group’s distribution segment is represented by IRWIN, which supplies medicines, medicinal products and medical equipment for Russian healthcare institutions all across the country. The company is also engaged in the state healthcare programmes for oncological and cardiovascular diseases, diabetes, tuberculosis, hepatitis A and B, and HIV infection providing drugs to the eligible categories of citizens.